R1 RCM Inc. found using ticker (RCM) now have 8 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 35 and 28 with the average target price sitting at 32.25. With the stocks previous close at 21.04 this would imply there is a potential upside of 53.3%. The 50 day MA is 24.8 while the 200 day moving average is 23.42. The company has a market cap of $6,299m. Find out more information at: https://www.r1rcm.com
The potential market cap would be $9,655m based on the market concensus.
R1 RCM Inc. provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers. It also provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. It serves healthcare providers, including health systems, hospitals, and physician groups. The company was formerly known as Accretive Health and changed its name to R1 RCM Inc. in January 2017. R1 RCM Inc. was incorporated in 2003 and is headquartered in Murray, Utah.
